';
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) announced more than $6 million in grant funding for organizations to establish or expand substance use disorder (SUD) services, community outreach, and education to underrepresented communities struggling with the opioid overdose crisis.
In 2020, overdose death rates increased 39 percent for Black Pennsylvanians, compared to 2019. In 2021, Black Pennsylvanians died from an overdose at a rate that was nearly two times higher than white Pennsylvanians.
Those eligible for this funding included organizations that provide services, outreach, and/or education to communities of color and promote access to harm reduction services, low-barrier SUD and medication-assisted treatment (MAT), recovery and peer supports, and/or offender reentry supports.
Through this funding award, 19 organizations are receiving grants up to $400,000 for a 12-month period beginning July 1, 2023, through June 30, 2024. Funds shall be applied toward a range of activities, including construction and building infrastructure, staffing, and evidence-based programming.
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) awarded $4 million in grant funding for the establishment of regional recovery hubs to enhance resources for individuals in recovery and promote recovery within communities across Pennsylvania.
The funding will allow each regional recovery hub to conduct an initial needs assessment for recovery support services in their specific region, including an estimate of individuals in need of these services and an analysis of their availability and accessibility. In addition, the hubs will develop a strategic plan, partnering with local organizations, that focuses on the importance of supporting multiple pathways to and through recovery, and will seek to promote recovery services in areas including peer support, family support, and self-care.
The regional recovery hubs throughout Pennsylvania will be designed to embed, expand, and promote a Recovery-Oriented-System of Care, which is a coordinated network of community-based services and supports that is person-centered, with the ultimate goal of improving the health, wellness, and quality of life for individuals in recovery from substance use disorder.
Grants up to $500,000 each will be awarded for the 15-month period beginning July 1, 2023, through September 29, 2024, to the following organizations serving the various regions:
Each grantee will use a hub and spoke model to provide recovery supports in their designated region. Each regional “hub” will support community-driven services that will serve as “spokes.” The hub will provide technical assistance and collaborate with a variety of community entities, sectors, and systems to enhance a recovery-supportive community and facilitate recovery support service delivery.
In addition, DDAP issued a Grant Initiative Funding Application (GIFA) for a regional recovery hub in Region 5, which includes York, Adams, Franklin, Fulton, Bedford, Cumberland, Perry, Dauphin, Lebanon, Huntington, Mifflin, Juniata, and Blair Counties.
The GIFA is available on DDAP’s website.
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) will offer an instructor-led, two-hour training titled, “Xylazine: A New Drug Additive.” Savage Sisters Recovery, a Pennsylvania nonprofit that provides trauma-informed recovery housing, harm reduction, outreach, and statewide education, will lead the training.
According to a recent New York Times article, “In Philadelphia, and increasingly in drug hot zones around the country, an animal tranquilizer called xylazine — known by street names like ‘tranq,’ ‘tranq dope’ and ‘zombie drug’ — is being used to bulk up illicit fentanyl, making its impact even more devastating.
“Xylazine causes wounds that erupt with a scaly dead tissue called eschar; untreated, they can lead to amputation. It induces a blackout stupor for hours, rendering users vulnerable to rape and robbery. When people come to, the high from the fentanyl has long since faded and they immediately crave more. Because xylazine is a sedative and not an opioid, it resists standard opioid overdose reversal treatments.”
This instructor-led training will provide information on national and statewide opioid statistics and updates on current drug supply trends, including critical information on xylazine. A demonstration of overdose reversal procedures when the presence of xylazine is suspected is also included in this training.
DDAP is holding two sessions of this training at its office in Harrisburg on May 25, 2023. Please visit DDAP’s Training Management System for details and to register. Pennsylvania Certification Board continuing education credits will be available for these sessions.
The Pennsylvania Department of Drug and Alcohol Programs (DDAP) is seeking provider input for a brief workforce survey. DDAP is interested in hearing providers’ perspective on which jobs and positions are in short supply or understaffed, the challenges providers face, attempts to address them, and solutions that DDAP should consider. Responses will help inform DDAP’s regulatory reform efforts.
The survey can be taken here.